Related Experiment Videos
Selective streptokinase infusion: clinical and laboratory correlates
Radiology
|September 1, 1983
Summary
Selective intra-arterial streptokinase (SK) infusion effectively treated acute peripheral arterial thromboembolic disease in 74% of patients. This low-dose method demonstrated a favorable benefit-risk ratio compared to systemic infusions, with manageable bleeding risks.
Area of Science:
- Vascular Medicine
- Interventional Radiology
Background:
- Acute thromboembolic conditions pose significant risks for limb and organ viability.
- Systemic thrombolytic therapy carries a high risk of major hemorrhage.
Purpose of the Study:
- To evaluate the efficacy and safety of selective intra-arterial streptokinase (SK) infusion for acute peripheral arterial thromboembolic disease.
- To compare the benefit-risk ratio of selective low-dose infusion versus systemic infusion.
Main Methods:
- Selective intra-arterial infusions of streptokinase (SK) were administered to 45 patients with acute thromboembolic conditions.
- The common regimen involved 5,000 units of SK/hour for 24–48 hours, with concurrent heparin infusion.
- Coagulation parameters were monitored throughout the infusion period.
Main Results:
- Significant thrombolysis was achieved in 80% of treated arteries.
- Clinical benefit was observed in 74% of patients.
- Minor bleeding occurred in 30% of patients, and major hemorrhages in 8% (4 patients), with no attributable strokes or fatalities.
Conclusions:
- Selective intra-arterial SK infusion is a moderately effective and safe treatment for acute peripheral arterial thromboembolic disease.
- Low-dose selective infusion offers an improved benefit-risk profile compared to systemic thrombolysis.